---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-038744"
form_type: "8-K"
ticker: "IMNM"
cik: "0001472012"
company_name: "Immunome Inc."
filed_at: "2024-03-26T23:59:59+00:00"
generated_at: "2026-06-04T07:48:26.163903+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Immunome completes acquisition of Ayala's AL102 Phase 3 desmoid tumor asset for $20M cash + stock

## Summary
- Acquisition of AL102 (Phase 3 gamma secretase inhibitor) and AL101; upfront $20M cash and 2,175,489 shares to Ayala.
- Potential milestone payments up to $37.5M upon development and commercial milestones.
- BMS license assumed: up to $142M clinical/regulatory milestones + $50M commercial milestones per product; royalties high single to low teen % on net sales.
- CEO states AL102 may establish new standard of care for desmoid tumors; preclinical programs advancing to Phase 1.

## SEC filing metadata
- accession: 0001104659-24-038744
- form_type: 8-K
- ticker: IMNM
- cik: 0001472012
- company_name: Immunome Inc.
- filed_at: 2024-03-26T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.01, 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472012/000110465924038744/0001104659-24-038744-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472012/000110465924038744/tm249326d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-038744
- JSON: https://secwatch.observer/filing/0001104659-24-038744.json
- Plain text: https://secwatch.observer/filing/0001104659-24-038744.txt

## Key facts
- M&A Transactions
  Immunome Inc. completed an acquisition involving Ayala Pharmaceuticals, Inc. for $20.0 million in cash (closed 2024-03-25).
  - Action: acquisition
  - Counterparty: Ayala Pharmaceuticals, Inc.
  - Consideration: $20.0 million in cash
  - Closing: 2024-03-25
  source text: by reference. Item 2.01 Completion of Acquisition or Disposition of Assets Pursuant to the terms of the Asset Purchase Agreement, Immunome (i) paid an upfront purchase price of $20.0 million in cash to Ayala, less certain adjustments, (ii) issued Ayala 2 ,175,489 shares of Immunome’s common stock (the “Shares”), (iii) assumed specified liabilities from Ayala, and
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472012/000110465924038744/0001104659-24-038744-index.htm
- Material Agreements
  Immunome Inc. entered into BMS License with Bristol-Myers Squibb Company valued at up to approximately $142 million.
  - Action: entry
  - Agreement: license
  - Counterparty: Bristol-Myers Squibb Company
  - Value: up to approximately $142 million
  source text: In November 2017, Ayala entered into a License Agreement with Bristol-Myers Squibb Company (“BMS”), as amended by that certain First Amendment to License Agreement dated as of May 4, 2020 (the “BMS License”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472012/000110465924038744/0001104659-24-038744-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.